Patient Screening

AI-matched candidates · Pre-screened eligibility · Screen failure prediction
Candidate funnel · ATLAS-204
47 candidates predicted to pass screening
wrldOS pre-screened 1,247 EHR records against your I/E criteria, checked concomitant medications against the protocol's prohibited drug list, and predicted screen failure probability for each candidate. Your CRCs engage only the high-probability cohort.
Pool
1,247
EHR records reviewed
Pre-screened
284
22.8% → diagnosis match
Matched
89
31.3% → I/E eligible
Predicted pass
47
52.8% → screen pass likely
Enroll target
38
vs 18 historical avg
Sort by
Candidates8 patients
PT-08471M.W. · 64/F
EXCELLENT
NSCLC stage IIIB · EGFR exon 19
94 match·100% eligible·8% fail risk
PT-09102R.S. · 71/M
EXCELLENT
NSCLC stage IV · EGFR L858R
92 match·100% eligible·11% fail risk
PT-07823T.K. · 58/F
EXCELLENT
NSCLC stage IIIA · EGFR exon 19
91 match·95% eligible·14% fail risk
PT-10245D.B. · 67/M
GOOD
NSCLC stage IIIB · EGFR L858R
87 match·92% eligible·18% fail risk
PT-08891J.M. · 62/F
GOOD
NSCLC stage IV · EGFR exon 21
84 match·88% eligible·22% fail risk
PT-09567A.L. · 70/F
GOOD
NSCLC stage IIIA · KRAS G12C
81 match·85% eligible·26% fail risk
PT-07429P.R. · 65/M
FAIR
NSCLC stage IIIB · EGFR exon 19
75 match·78% eligible·35% fail risk
PT-10098S.H. · 73/F
FAIR
NSCLC stage IV · EGFR L858R
71 match·72% eligible·39% fail risk
PT-08471EXCELLENT
M.W. · 64/F
NSCLC stage IIIB · EGFR exon 19
94
AI match
100%
Eligible
8%
Fail risk
Inclusion/Exclusion · 14 criteria
✓Histologically confirmed NSCLC
✓EGFR mutation positive
✓Stage IIIA-IV per AJCC v8
✓ECOG performance status 0-1
✓Adequate organ function
✓No prior EGFR-TKI exposure